InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced the appointment of Heather M. Hamel, J.D. as its Chief Legal Officer and General Counsel. In her role, Ms. Hamel will lead the company's legal and intellectual property functions, and provide strategic guidance to the company's Board of Directors and executive management team. Ms. Hamel will also be responsible for the oversight of certain other functions, including business development, human resources and external communications. Prior to this appointment, Ms. Hamel served as the company's Vice Preside

4 - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Issuer)

8-K - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Filer)

8-K - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Filer)

8-K - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Filer)

ARS - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Filer)

DEF 14A - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Filer)

8-K - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Filer)

8-K - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Filer)

8-K - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Filer)

10-Q - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Filer)

8-K - INVIVO THERAPEUTICS HOLDINGS CORP. (0001292519) (Filer)

Study did not achieve primary endpoint of defined improvement on standard impairment scale InVivo to evaluate full data set and strategic options for the company InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries (SCI), today announced topline results from the company's INSPIRE 2.0 study, which was designed to evaluate the safety and probable benefit of InVivo's investigational Neuro-Spinal Scaffold™, a bioresorbable scaffold-based device in development for patients with acute SCI. The study did not meet its primary endpoint, which was assessed by the proportion of tre

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has closed its previously announced registered direct offering for the sale and issuance of 154,000 shares of the Company's common stock and pre-funded warrants to purchase up to 369,810 shares of common stock to a single healthcare-focused institutional investor. The Company also closed its previously announced private placement priced at-the-market under Nasdaq rules for the sale and issuance of pre-funded warrants to purchase up to 1,190,476 shares of common stock with the same investor in the

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the sale and issuance of 523,810 shares of the Company's common stock (or pre-funded warrants in lieu thereof), in a registered direct offering priced at-the-market under Nasdaq rules. Concurrently with the registered direct offering, the Company entered into a definitive agreement with the investor in the registered direct offering for the sale and issuance of 1,190,476 shares of common stock (or

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming H.C. Wainwright 24th Annual Global Investment Conference, which runs from September 12 – 14, 2022. Dr. Toselli and company management will also be available to participate in virtual one-on-one meetings with registered investors attending the conference. A webcast of Dr. Toselli's presentation will be available on the Investor Relations - Events section of the company website at https://investors.invivotherap

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced the appointment of Heather M. Hamel, J.D. as its Chief Legal Officer and General Counsel. In her role, Ms. Hamel will lead the company's legal and intellectual property functions, and provide strategic guidance to the company's Board of Directors and executive management team. Ms. Hamel will also be responsible for the oversight of certain other functions, including business development, human resources and external communications. Prior to this appointment, Ms. Hamel served as the company's Vice Preside

Manuscript details patient outcomes through 24-month follow up visit InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) today announced the publication of a peer-reviewed manuscript in Neurosurgery describing the previously disclosed 12- and 24-month data from the Company's single-arm INSPIRE 1.0 Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury). The publication is titled "Acute Implantation of a Bioresorbable Polymer Scaffold in Patients with Complete Thoracic Spinal Cord Injury: 24-Month Follow-up from the INSPIRE Study." Richard Toselli, M.D., InVivo's President and Chief E

Topline data expected to be reported in Q1 2023 InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has completed enrollment in the INSPIRE 2.0 Study for patients with acute spinal cord injury. The 20-patient study is a randomized, controlled trial featuring 10 subjects in each study arm, designed to enhance the existing clinical evidence for the Neuro-Spinal Scaffold™ from the Company's INSPIRE 1.0 study. "Reaching full enrollment in our INSPIRE 2.0 study is a significant advancement in our research and development efforts towards a potential t

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) today announced a 1-for-25 reverse stock split of its common stock and a proportionate reduction in its authorized common stock. The company anticipates the reverse stock split will become effective at 5:00 p.m. Eastern Time on April 26, 2022, and shares of InVivo Therapeutics common stock will trade on a post-split basis under the company's existing trading symbol, "NVIV," at the market open on April 27, 2022. The new CUSIP number for the company's common stock following the reverse stock split will be CUSIP 46186M 605/ISIN US46186M6057. At the effective time of the reverse stock split, every 25 shares of InVivo Therapeutics common stock wi

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming virtual H.C. Wainwright BioConnect Conference, which runs from January 10 – 13, 2022. Dr. Toselli's presentation will provide an overview of the company and will also highlight recent updates to the company's clinical program. A webcast of Dr. Toselli's presentation will be available on the Investor Relations - Events section of the company website at https://investors.invivotherapeutics.com/events, beginning

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming H.C. Wainwright Annual Global Investment Conference, which runs from September 13 – 15, 2021. The conference will be held in a virtual format. A webcast of Dr. Toselli's presentation will be available on the Investor Relations - Events section of the company website at https://investors.invivotherapeutics.com/events, beginning September 13, 2021 at 7:00 am ET. Dr. Toselli and company management will also be a

Gainers BioSig Technologies (NASDAQ:BSGM) stock increased by 7.7% to $0.96 during Monday's after-market session. The company's market cap stands at $8.9 million. Coeptis Therapeutics (NASDAQ:COEP) shares rose 6.64% to $0.48. The market value of their outstanding shares is at $16.3 million. Alzamend Neuro (NASDAQ:ALZN) stock rose 6.56% to $0.97. The market value of their outstanding shares is at $6.4 million. China Pharma Holding (AMEX:CPHI) stock increased by 5.7% to $0.1. The company's market cap stands at $5.3 million. AIM ImmunoTech (AMEX:AIM) shares rose 5.54% to $0.45. The market value of their outstanding shares is at $21.9 million. Better Therapeutics (NASDAQ:BTTX) stock moved u

Shares of Big Lots, Inc. (NYSE:BIG) fell sharply during Monday’s session after the company reported preliminary fourth-quarter results. Also, Loop Capital downgraded the stock from Hold to Sell and lowered its price target from $6 to $1. Big Lots shares dipped 31.3% to $3.6850 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Millennium Group International Holdings Limited (NASDAQ:MGIH) surged 250% to $3.61 after YC 1926 (BVI) Limited reported an 88.89% stake in the company in a 13G filing on Friday. Beamr Imaging Ltd. (NASDAQ:BMR) shares climbed 241.5% to $7.20 after the company announced it will present its joint research relating to automated vide

Gainers Renalytix (NASDAQ:RNLX) stock rose 490.4% to $2.25 during Monday's regular session. The market value of their outstanding shares is at $112.4 million. Regencell Bioscience (NASDAQ:RGC) stock rose 39.91% to $10.39. The market value of their outstanding shares is at $135.2 million. Genenta Science (NASDAQ:GNTA) shares increased by 31.84% to $4.14. The market value of their outstanding shares is at $75.4 million. T2 Biosystems (NASDAQ:TTOO) stock rose 29.94% to $6.35. The company's market cap stands at $25.7 million. Sangamo Therapeutics (NASDAQ:SGMO) stock moved upwards by 26.04% to $0.72. The company's market cap stands at $128.3 million. Organovo Holdings (NASDAQ:ONVO) shares m

Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock rose 122.5% to $4.05 during Thursday's pre-market session. The company's market cap stands at $2.2 million. Titan Pharma (NASDAQ:TTNP) stock moved upwards by 27.59% to $8.0. The company's market cap stands at $6.0 million. Trxade Health (NASDAQ:MEDS) shares rose 18.73% to $5.32. The company's market cap stands at $6.4 million. Elicio Therapeutics (NASDAQ:ELTX) shares moved upwards by 17.8% to $3.97. The company's market cap stands at $38.1 million. Nutex Health (NASDAQ:NUTX) stock increased by 17.63% to $0.13. The market value of their outstanding shares is at $97.9 million. Mineralys Therapeutics (NASDAQ:MLYS) shares rose 16.51% to

Shares of The Walt Disney Company (NYSE:DIS) rose in today’s pre-market trading following the release of quarterly results. The company reported better-than-expected earnings for its first quarter and declared a cash dividend of 45 cents per share. The company announced a new share repurchase program and said it expects fiscal 2024 earnings of roughly $4.60 per share. Disney also announced a $1.5 billion investment in leading video game company Epic Games. Disney shares gained 5.9% to $105.00 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers Hitek Global Inc. (NASDAQ:HKIT) gained 224.5% to $3.70 in pre-market trading after jumping more than 60% on

Shares of FMC Corporation (NYSE:FMC) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter results. FMC posted adjusted earnings of $1.07 per share, missing market estimates of $1.08 per share. The company’s quarterly sales came in at $1.15 billion versus expectations of $1.25 billion. FMC shares dipped 9.8% to $54.51 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) jumped 144.4% to $0.5427 after dipping around 26% on Monday. Tenax Therapeutics, Inc. (NASDAQ:TENX) jumped 96% to $17.13 after the company announced the USPTO granted notice of allowance for t

Gainers InVivo Therapeutics Hldg (NASDAQ:NVIV) stock rose 306.0% to $0.9 during Tuesday's regular session. The company's market cap stands at $2.7 million. Cyclerion Therapeutics (NASDAQ:CYCN) stock rose 56.02% to $4.4. The company's market cap stands at $10.7 million. Tenax Therapeutics (NASDAQ:TENX) stock increased by 41.62% to $12.35. The market value of their outstanding shares is at $3.6 million. Equillium (NASDAQ:EQ) stock increased by 35.62% to $1.08. The company's market cap stands at $38.1 million. Karyopharm Therapeutics (NASDAQ:KPTI) stock moved upwards by 31.11% to $1.77. The market value of their outstanding shares is at $202.7 million. Immunome (NASDAQ:IMNM) stock increas